Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews

Overview

Journal Drug Saf

Specialties Pharmacology
Toxicology

Date 2019 Sep 26

PMID 31552603

Citations 4

Authors

Emanuel Raschi

Matteo Bianchin

Milo Gatti

Alessandro Squizzato

Fabrizio De Ponti

Affiliations

Soon will be listed here.

Abstract

Direct oral anticoagulants are now recommended by major guidelines as first-choice agents for both stroke prevention in non-valvular atrial fibrillation and treatment/prevention of venous thromboembolism in non-cancer patients. Although there are no published head-to-head trials comparing different direct oral anticoagulants, a growing body of evidence from indirect comparisons and observational studies is suggesting that each direct oral anticoagulant may have a specific risk profile. This review aims to (1) synthesize and critically assess the latest evidence in comparative effectiveness and safety research in the aforementioned consolidated therapeutic uses, by performing an overview of systematic reviews and (2) highlight current challenges, namely underexplored areas, where research should be directed, also considering ongoing unpublished studies. The evidence gathered so far on the risk-benefit profile of direct oral anticoagulants is appraised in the light of existing guidelines to discuss whether further implementation should be proposed.

Citing Articles

Efficacy and Safety of Direct Oral Anticoagulants in Pediatric Venous Thromboembolism: A Systematic Review and Meta-Analysis.

Geng Y, Meng C, Gao T, Li S, Bi L, Wang Y Indian J Pediatr. 2023; .

PMID: 38117441 DOI: 10.1007/s12098-023-04952-8.

DOAC plasma concentration upon hospital admission in a cohort of trauma patients. An observational real-life study.

Ruoff C, Schochl H, Fritsch G, Voelckel W, Zipperle J, Gratz J Eur J Trauma Emerg Surg. 2023; 49(6):2543-2551.

PMID: 37500912 DOI: 10.1007/s00068-023-02334-5.

Bleeding Outcomes After Dental Extraction in Patients Under Direct-Acting Oral Anticoagulants vs. Vitamin K Antagonists: A Systematic Review and Meta-Analysis.

Hua W, Huang Z, Huang Z Front Pharmacol. 2021; 12:702057.

PMID: 34776943 PMC: 8585494. DOI: 10.3389/fphar.2021.702057.

The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia.

Gatti M, Raschi E, Poluzzi E, Martignani C, Salvagni S, Ardizzoni A Curr Heart Fail Rep. 2020; 17(6):365-383.

PMID: 33025463 PMC: 7537958. DOI: 10.1007/s11897-020-00485-9.

References

Wei A, Gu Z, Zhang C, Ding Y, Liu D, Li J . Increased risk of myocardial infarction with dabigatran etexilate: fact or fiction? A critical meta-analysis of over 580,000 patients from integrating randomized controlled trials and real-world studies. Int J Cardiol. 2018; 267:1-7. DOI: 10.1016/j.ijcard.2018.05.048. View

Tadrous M, Gagne J, Sturmer T, Cadarette S . Disease risk score as a confounder summary method: systematic review and recommendations. Pharmacoepidemiol Drug Saf. 2012; 22(2):122-9. PMC: 3691557. DOI: 10.1002/pds.3377. View

Schisterman E, Cole S, Platt R . Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009; 20(4):488-95. PMC: 2744485. DOI: 10.1097/EDE.0b013e3181a819a1. View

Raschi E, Bianchin M, Ageno W, De Ponti R, De Ponti F . Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies. Drug Saf. 2016; 39(12):1175-1187. PMC: 5107188. DOI: 10.1007/s40264-016-0464-3. View

Paravattil B, Elewa H . Approaches to Direct Oral Anticoagulant Selection in Practice. J Cardiovasc Pharmacol Ther. 2018; :1074248418793137. DOI: 10.1177/1074248418793137. View

Lee C, Gerds T, Carlson N, Bonde A, Gislason G, Lamberts M . Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018; 72(1):17-26. DOI: 10.1016/j.jacc.2018.04.036. View

Prada-Ramallal G, Takkouche B, Figueiras A . Summarising the Evidence for Drug Safety: A Methodological Discussion of Different Meta-Analysis Approaches. Drug Saf. 2017; 40(7):547-558. DOI: 10.1007/s40264-017-0518-1. View

Steffel J, Verhamme P, Potpara T, Albaladejo P, Antz M, Desteghe L . The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39(16):1330-1393. DOI: 10.1093/eurheartj/ehy136. View

Maura G, Pariente A, Alla F, Billionnet C . Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study. Pharmacoepidemiol Drug Saf. 2017; 26(11):1367-1377. PMC: 5697683. DOI: 10.1002/pds.4268. View

10.

Gelosa P, Castiglioni L, Tenconi M, Baldessin L, Racagni G, Corsini A . Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res. 2018; 135:60-79. DOI: 10.1016/j.phrs.2018.07.016. View

11.

Raschi E, Poluzzi E, Koci A, Salvo F, Pariente A, Biselli M . Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol. 2015; 80(2):285-93. PMC: 4541976. DOI: 10.1111/bcp.12611. View

12.

Lip G, Banerjee A, Boriani G, Chiang C, Fargo R, Freedman B . Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest. 2018; 154(5):1121-1201. DOI: 10.1016/j.chest.2018.07.040. View

13.

Deitelzweig S, Farmer C, Luo X, Vo L, Li X, Hamilton M . Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies. Curr Med Res Opin. 2017; 33(9):1583-1594. DOI: 10.1080/03007995.2017.1347090. View

14.

Capodanno D, Huber K, Mehran R, Lip G, Faxon D, Granger C . Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019; 74(1):83-99. DOI: 10.1016/j.jacc.2019.05.016. View

15.

Maura G, Billionnet C, Drouin J, Weill A, Neumann A, Pariente A . Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016. BMJ Open. 2019; 9(4):e026645. PMC: 6500377. DOI: 10.1136/bmjopen-2018-026645. View

16.

Raschi E, Bianchin M, Fantoni C, Ageno W, De Ponti F, De Ponti R . Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?. Intern Emerg Med. 2017; 12(7):923-934. DOI: 10.1007/s11739-017-1724-7. View

17.

Diener H, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J . Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur Heart J. 2016; 38(12):852-859. PMC: 5837588. DOI: 10.1093/eurheartj/ehv643. View

18.

Douros A, Azoulay L, Yin H, Suissa S, Renoux C . Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury. J Am Coll Cardiol. 2018; 71(10):1105-1113. DOI: 10.1016/j.jacc.2018.01.009. View

19.

Kearon C, Akl E, Ornelas J, Blaivas A, Jimenez D, Bounameaux H . Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2):315-352. DOI: 10.1016/j.chest.2015.11.026. View

20.

Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J . Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018; 362:k2505. PMC: 6031213. DOI: 10.1136/bmj.k2505. View